GoldenGolden
Advanced Search
venBio

venBio

A venture capital and private equity firm making early and late-stage investments in life science, healthcare, and therapeutics companies.

venBio is a venture capital and private equity firm early and late-stage investment in life science, healthcare, and therapeutics companies that is headquartered in San Francisco, California and was founded in 2011 by Corey Goodman, Kurt con Emter, and Robert Adelman.

Investments

As of November 2019 venBio has made 42 investments, has 20 companies in its portfolio, and has made 18 exits. Notable investments made by venBio include: Inbrace, Neurogastrix, Swfit Health Systems, Aeovian Pharmaceuticals, Checkmate Pharmaceuticals, Turning Point Therapeutics, Precision BioSciences, Akero Therapeutics, Oncobiologics, and Corvus Pharmaceuticals.

Investment funds
Fund II

On May 6, 2016 venBio announced raising $315 million for their second venture capital fund; exceeding its initial target of $250 million. The fund has three strategic limited parters which are Amgen, Merk, and Baxalta, and a group of financial limited partners. At the time of announcing their second fund venBio also announced adding Aaron Royston and Jaume Pons to their investment team. Robert Adelman, the managing partner of venBio, made the following statement regarding the firms second venture capital fund:

We believe our fund model is unique. With the return of Amgen and Baxalta, along with the addition of Merck, the commitment from our Strategic Limited Partners is now larger than ever. Our investment model will remain the same. We continue to seek to finance promising life sciences companies that focus on therapeutics which we believe will make a difference for unmet medical needs.

Timeline

June 3, 2021
VenBio raises $550,000,000 in its latest fund.
2009
venBio was founded.

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Amirah Al Idrus
June 3, 2021
FierceBiotech
VenBio banked about $550 million in its latest fund to invest in a dozen or so new life sciences companies as well as to support its portfolio companies in financings both private and public. As with its three predecessors, the firm will invest Fund IV primarily in companies "developing biopharmaceuticals for unmet medical needs."

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.